Illumina names Agilent executive as new CEO
Illumina Inc. (ILMN) on Tuesday announced that its board has appointed Agilent Technologies Inc. (A) senior vice president Jacob Thaysen as its new CEO, effective Sept. 25. The DNA sequencing company faced leadership turmoil after its proxy fight earlier this year with activist investor Carl Icahn, and CEO Francis deSouza stepped down in June. Evercore ISI analysts wrote in a research note last week that Illumina shares could be poised for a turnaround under new leadership, noting that "new CEOs can be powerful catalysts." Thaysen's "extensive background and experience in genomics, life sciences, and technology fits closely with Illumina's mission," the company said in a statement Tuesday, adding that the executive since 2018 has overseen the unit responsible for Agilent's analytical instrument portfolio, informatics, and cell analysis franchise. Illumina shares gained 0.6% premarket on Tuesday and have declined 16.7% in the year to date, while the S&P 500 has gained 17.6%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-05-23 0746ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
How to Invest Like Warren Buffett
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025